OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
300214$8.5655

Shandong Rike Chemical Co Ltd

Commodity ChemicalsVerified

Shandong Rike Chemical Co Ltd has a market capitalization of CNY 3.98 billion and an enterprise value to revenue ratio of 1.58, indicating a relatively low valuation compared to revenue. The company's debt-to-equity ratio is 0.81, suggesting a moderate level of leverage. However, its liquidity is assessed as medium, and it has negative net cash after subtracting total debt, which could pose challenges in meeting short-term obligations. In terms of profitability, the company's operating cash flow is CNY 131.12 million, but its capital expenditures are negative at CNY -161.95 million, indicating a net outflow of cash from investing activities. This suggests the company is not currently investing in new projects or capacity expansion, which could affect long-term growth. The company's return on invested capital (ROIC) and other profitability metrics are not provided, but the industry_config for Commodity Chemicals emphasizes ROIC and operating margins as key performance indicators. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to regional economic or regulatory risks. The absence of segment or geographic breakdown in the financial data limits the ability to assess exposure to different markets. The company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided. The absence of forward-looking guidance makes it difficult to assess the company's future performance. The company's capital expenditures are negative, which may indicate a lack of investment in new projects or capacity expansion, potentially limiting future growth. The company's risk profile includes medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company has not disclosed any dilutive events or share issuance plans, and the dilution risk is assessed as low. Recent events and filings are not disclosed in the available data, so no specific developments can be reported. The company's financial statements and disclosures are limited to the data provided, which does not include recent earnings calls, regulatory filings, or other public announcements.

30-day price · 300214+1.99 (+29.7%)
Low$6.69High$9.97Close$8.70As of20 May, 00:00 UTC
Profile
CompanyShandong Rike Chemical Co Ltd
Ticker300214.SZ
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Shandong Rike Chemical Co Ltd is a Chinese chemical manufacturing company that produces and sells commodity chemicals, primarily serving industrial and consumer markets.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92 based on verified market data.

Shandong Rike Chemical Co Ltd has a market capitalization of CNY 3.98 billion and an enterprise value to revenue ratio of 1.58, indicating a relatively low valuation compared to revenue. The company's debt-to-equity ratio is 0.81, suggesting a moderate level of leverage. However, its liquidity is assessed as medium, and it has negative net cash after subtracting total debt, which could pose challenges in meeting short-term obligations. In terms of profitability, the company's operating cash flow is CNY 131.12 million, but its capital expenditures are negative at CNY -161.95 million, indicating a net outflow of cash from investing activities. This suggests the company is not currently investing in new projects or capacity expansion, which could affect long-term growth. The company's return on invested capital (ROIC) and other profitability metrics are not provided, but the industry_config for Commodity Chemicals emphasizes ROIC and operating margins as key performance indicators. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to regional economic or regulatory risks. The absence of segment or geographic breakdown in the financial data limits the ability to assess exposure to different markets. The company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided. The absence of forward-looking guidance makes it difficult to assess the company's future performance. The company's capital expenditures are negative, which may indicate a lack of investment in new projects or capacity expansion, potentially limiting future growth. The company's risk profile includes medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company has not disclosed any dilutive events or share issuance plans, and the dilution risk is assessed as low. Recent events and filings are not disclosed in the available data, so no specific developments can be reported. The company's financial statements and disclosures are limited to the data provided, which does not include recent earnings calls, regulatory filings, or other public announcements.
Key takeaways
  • The company has a moderate debt-to-equity ratio of 0.81, indicating a balanced capital structure.
  • The enterprise value to revenue ratio of 1.58 suggests a relatively low valuation compared to revenue.
  • The company's liquidity is assessed as medium, with negative net cash after subtracting total debt.
  • The company is not currently investing in new projects or capacity expansion, as indicated by negative capital expenditures.
  • The company's growth trajectory is uncertain due to the lack of forward-looking guidance and investment in new projects.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$3.74B
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow$131.1M
CapEx-$161.9M
Free cash flow
Total assets
Total liabilities$2.65B
Total equity$2.39B
Cash & equivalents
Long-term debt$1.94B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$3.74B-$3.7M-$29.7M$29.5M
FY-1$3.52B-$94.6M-$72.9M-$549.0M
FY-2$2.54B$96.5M$84.6M-$593.0M
FY-3$2.76B$246.4M$196.5M$25.8M
FY-4$2.77B$245.7M$190.2M$57.2M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$5.04B$2.39B
FY-1$5.18B$2.45B
FY-2$3.94B$2.58B
FY-3$3.05B$2.53B
FY-4$2.89B$2.36B
PeriodOCFCapExFCFSBC
FY0$131.1M-$161.9M$29.5M
FY-1-$212.4M-$573.5M-$549.0M
FY-2-$15.7M-$719.7M-$593.0M
FY-3$227.7M-$211.8M$25.8M
FY-4$107.0M-$171.8M$57.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$913.0M$5.6M$2.1M
FQ-1$915.0M$195.2k-$33.7M
FQ-2$869.8M$3.7M$2.9M
FQ-3$1.03B$4.3M$9.8M
FQ-4$931.6M-$11.5M-$8.6M
FQ-5$1.10B-$44.9M-$15.8M
FQ-6$986.6M-$5.8M-$10.0M
FQ-7$821.4M-$33.0M-$33.6M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$5.02B$2.39B$344.5M
FQ-1$5.04B$2.39B
FQ-2$4.97B$2.42B$107.6M
FQ-3$5.01B$2.42B
FQ-4$5.02B$2.44B$172.0M
FQ-5$5.18B$2.45B
FQ-6$4.96B$2.46B$220.7M
FQ-7$4.57B$2.49B
PeriodOCFCapExFCFSBC
FQ0$4.8M-$16.1M
FQ-1$131.1M-$161.9M
FQ-2$64.9M-$79.2M
FQ-3$11.2M-$67.5M
FQ-4$14.1M-$53.2M
FQ-5-$212.4M-$573.5M
FQ-6-$41.2M-$490.4M
FQ-7-$76.4M-$405.8M
Valuation
Market price$8.56
Market cap$3.98B
Enterprise value$5.92B
P/E
Reported non-GAAP P/E
EV/Revenue1.6
EV/Op income
EV/OCF45.1
P/B
P/Tangible book
Tangible book
Net cash-$1.94B
Current ratio
Debt/Equity0.8
ROA
ROE
Cash conversion
CapEx/Revenue-4.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric300214Activity
Op margin0.4% medp25 -8.0% · p75 16.0%
Net margin2.3% medp25 -11.6% · p75 11.8%
Gross margin20.8% medp25 14.9% · p75 24.0%
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-4.3%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity81.0%59.0% medp25 54.9% · p75 72.9%top quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 01:57 UTCJob: 79da672b